Studies indicate that c-Abl might be a promising therapeutic target for α-synucleinopathy [24, 25, 45, 71] and a recent study demonstrated that a pharmacological c-Abl inhibitor, nilotinib (Nilo) enable to cross blood brain barrier [72, 73]. The gene discussed is ABL1; the disease is synucleinopathy.